欧康医药：董事会秘书兼财务总监曹永强辞任

Core Viewpoint - The announcement from Europharma indicates a significant leadership change with the resignation of Mr. Cao Yongqiang as Secretary of the Board and Chief Financial Officer effective December 12, 2025, due to personal reasons [1] Group 1 - Mr. Cao Yongqiang will no longer hold any positions within the company or its subsidiaries after his resignation [1] - Chairman Zhao Zhuojun will temporarily assume the relevant responsibilities until a new appointment is made [1]